A Translational Study of TNF-Alpha Antagonists as an Adjunctive Therapy for Preventing Hemophilic Arthropathy
Open Access
- 27 December 2019
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (1) , 75
Abstract
Repeated intra-articular hemorrhages lead to hemophilic arthropathy in severe hemophilia. Inflammation and pro-inflammatory cytokines (e.g., tumor necrosis factor alpha (TNFα)) might be involved in this pathogenesis. We hypothesized that anti-TNFα may provide adjuvant protection for hemophilic arthropathy management. We measured TNFα in synovial lavage from hemophilia mice subjected to hemarthrosis induction and synovial fluid from patients with hemophilic arthropathy (n = 5). In hemophilia mice, recurrent hemarthroses were induced, anti-TNFα was initiated either from day (D)7 after one hemarthrosis episode or D21 after three hemarthroses episodes (n ≥ 7/treatment group). In patients with hemophilic arthropathy (16 patients with 17 affected joints), a single dose of anti-TNFα was administered intra-articularly. Efficacy, characterized by synovial membrane thickness and vascularity, was determined. Elevated TNFα in synovial lavage was found in the hemophilia mice and patients with hemophilic arthropathy. Hemophilia mice subjected to three hemarthroses developed severe synovitis (Synovitis score of 6.0 ± 1.6). Factor IX (FIX) replacement alone partially improved the pathological changes (Synovitis score of 4.2 ± 0.8). However, anti-TNFα treatment initiated at D7, not D21, significantly provided protection (Synovitis score of 1.8 ± 0.9 vs. 3.9 ± 0.3). In patients with hemophilic arthropathy, intra-articular anti-TNFα significantly decreased synovial thickness and vascularity during the observed period from D7 to D30. Collectively, this preliminary study seems to indicate that TNFα may be associated with the pathogenicity of hemophilic arthropathy and anti-TNFα could provide adjuvant protection against hemophilic arthropathy. Further studies are required to confirm the preliminary results shown in this study.Keywords
This publication has 48 references indexed in Scilit:
- Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970sBlood, 2013
- A single intra‐articular injection with IL‐4 plus IL‐10 ameliorates blood‐induced cartilage degeneration in haemophilic miceBritish Journal of Haematology, 2012
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Double Anti-angiogenic and Anti-inflammatory Protein Valpha Targeting VEGF-A and TNF-α in Retinopathy and PsoriasisJournal of Biological Chemistry, 2011
- Neoangiogenesis contributes to the development of hemophilic synovitisBlood, 2011
- IL‐1β, IL‐6, KC and MCP‐1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosisHaemophilia, 2009
- Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IXBlood, 2008
- Interleukin‐10 protects against blood‐induced joint damageBritish Journal of Haematology, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritisArthritis & Rheumatism, 2000